Journal ID (nlm-ta): Ann Clin Transl Neurol
Journal ID (iso-abbrev): Ann Clin Transl Neurol
Journal ID (doi): 10.1002/(ISSN)2328-9503
Journal ID (publisher-id): ACN3
Title:
Annals of Clinical and Translational Neurology
Publisher:
John Wiley and Sons Inc.
(Hoboken
)
ISSN
(Electronic):
2328-9503
Publication date
(Electronic):
31
October
2018
Publication date Collection:
December
2018
Volume: 5
Issue: 12
(
doiID:
10.1002/acn3.2018.5.issue-12
)
Pages: 1460-1477
Affiliations
[
1
]
Institute for Neurodegenerative Disorders
New Haven
Connecticut
[
2
]
The Michael J. Fox Foundation for Parkinson's Research
New York
New York
[
3
]
University of Pennsylvania
Philadelphia
Pennsylvania
[
4
]
University of Iowa
Iowa City
Iowa
[
5
]
Northwestern University
Chicago
Illinois
[
6
]
Eli Lilly and Company
New York
New York
[
7
]
University of California
San Francisco
California
[
8
]
National Institute on Aging
NIH
Bethesda
Maryland
[
9
]
Clinical Trials Coordination Center
University of Rochester
Rochester
New York
[
10
]
Paracelsus‐Elena Klinik
Kassel
Germany
[
11
]
University of California
San Diego
California
[
12
]
Indiana University
Indianapolis
Indianapolis
[
13
]
Stanford University Medical Center
Stanford
California
Author notes
[*]
[*
]
Correspondence
Kenneth Marek, Institute for Neurodegerative Disorders, 60 Temple St, Suite 8A, New
Haven, CT 06510. Tel: 203 4014353; Fax 203 401 4301; E‐mail:
kmarek@
123456indd.org
[†]
Parkinson's Progression Markers Initiative Authors.
Article
Publisher ID:
ACN3644
DOI: 10.1002/acn3.644
PMC ID: 6292383
PubMed ID: 30564614
SO-VID: da062f9e-a99e-4c63-bf31-656a028b8f38
Copyright © © 2018 The Authors.
Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
License:
This is an open access article under the terms of the
http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original
work is properly cited, the use is non‐commercial and no modifications or adaptations
are made.
Page count
Figures: 1,
Tables: 6,
Pages: 18,
Words: 14346
Funded by: Bristol‐Myers Squibb
Funded by: Covance
Funded by: Eli Lilly and Company
Funded by: Biogen
Funded by: Genentech
Funded by: UCB
Funded by: F. Hoffmann‐La Roche
Funded by: GE Healthcare
Funded by: Avid Radiopharmaceuticals
Funded by: Michael J. Fox Foundation for Parkinson's Research
Funded by: Merck
Funded by: Lundbeck
Funded by: GlaxoSmithKline
Funded by: Piramal
Funded by: Meso Scale Diagnostics
Funded by: Pfizer
Funded by: AbbVie
This work was funded by
Bristol‐Myers Squibb grant ;
Covance grant ;
Eli Lilly and Company grant ;
Biogen grant ;
Genentech grant ;
UCB grant ;
F. Hoffmann‐La Roche grant ;
GE Healthcare grant ;
Avid Radiopharmaceuticals grant ;
Michael J. Fox Foundation for Parkinson's Research grant ;
Merck grant ;
Lundbeck grant ;
GlaxoSmithKline grant ;
Piramal grant ;
Meso Scale Diagnostics grant ;
Pfizer grant ;
AbbVie grant .